

![]() |
Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis |
|
Authors | ![]() | |
Published in | Medical Decision Making. 2018, vol. 38, no. 6, p. 719-729 | |
Abstract | Decision makers often need to assess the real-world effectiveness of new drugs prelaunch, when phase II/III randomized controlled trials (RCTs) but no other data are available. | |
Identifiers | PMID: 30074882 | |
Full text | ||
Structures | ||
Research groups | Mécanisme de l'inflammation articulaire (44) Recherche clinique en rhumatismes inflammatoires (1010) | |
Citation (ISO format) | DIDDEN, Eva-Maria et al. Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis. In: Medical Decision Making, 2018, vol. 38, n° 6, p. 719-729. doi: 10.1177/0272989X18775975 https://archive-ouverte.unige.ch/unige:110686 |